LexBlog IP

AUGUST 30, 2023

It has been reported that Celltrion has finalized a settlement with Johnson & Johnson (“J&J”) in the United States relating to CT-P43, Celltrion’s ustekinumab biosimilar to J&J’s STELARA®, which would permit Celltrion to launch the product in the U.S. market on March 7, 2025, if approved by FDA.

Settlement 40

Settlement Confidentiality Marketing Marketing 40

SpicyIP

MARCH 1, 2025

1925 As of 26th February, 2025 , Kindle users will no longer be able to use the feature Download or Transfer via USB, for Kindle Purchased books, as Amazon is discontinuing the feature. What Kindle sells, instead of books, is licenses. Kindle Content is licensed, not sold, to you by the Content Provider.

Copying 59

Copying Editing Licensing Copyright 59

LexBlog IP

DECEMBER 13, 2023

The post Janssen and Samsung Bioepis Settle STELARA (Ustekinumab) Litigation appeared first on Big Molecule Watch.

Litigation 52

Litigation Settlement Licensing Marketing 52

LexBlog IP

FEBRUARY 23, 2024

On February 15, Alvotech announced that it reached more settlement agreements with Johnson & Johnson for ATV04, Alvotech’s biosimilar to STELARA (ustekinumab). Alvotech is still awaiting FDA approval of AVT04 in the United States, but has already secured a licensing agreement with Johnson & Johnson for the U.S.

Settlement 40

Settlement Marketing Marketing Licensing 40

Bio Law Blog

JUNE 21, 2020

settled three Inter Partes Review (IPR) proceedings concerning patents covering Alexion’s blockbuster humanized monoclonal antibody drug Soliris®, with Amgen obtaining a royalty-free license for marketing a biosimilar prior to expiration of the patents at issue. and Alexion Pharmaceuticals Inc. an eculizumab product.

Marketing 52

Marketing Marketing Settlement Patent 52

LexBlog IP

MARCH 6, 2024

On February 29, Biocon Biologics Ltd announced that it signed a settlement and license agreement with Janssen Biotech Inc. The agreement allows Biocon to launch in the United States in February 2025, pending FDA approval. 10,961,307, which claims methods of treating ulcerative colitis with ustekinumab. Amgen secured a U.S.

Marketing 40

Marketing Marketing Settlement Licensing 40

SpicyIP

JULY 8, 2024

Here is our recap of last week’s top IP developments including summary of the posts on the DHC’s direction to frame a code of conduct for Patent and Trademark Agents, MHC’s decision on prior arts, and the settlement between Dabur and Dhruv Rathee of their trademark and copyright dispute. Microsoft Technology Licensing LLC v.

Invention 59

Invention Art Trademark Patent Application 59

The IPKat

FEBRUARY 29, 2024

Sony maintains that the worldwide copyright for the recordings is held by Experience Hendrix LLC and Authentic Hendrix LLC, who license the rights to exploit and distribute the recordings to them. It is likely therefore that it will stand to be determined by a High Court judge some time in 2025.

Reporting 111

Reporting Copyright Contracts Settlement 111

SpicyIP

MARCH 15, 2024

This post does not, in any manner, get into the arena of willingness or unwillingness of defendants to enter into a licensing agreement. Since parties could not arrive at a settlement, ID initiated patent infringement proceedings against the defendants in UK, Germany and India. That is a different matter altogether.

Patent Infringement 59

Patent Infringement Settlement Patent Licensing 59

LexBlog IP

NOVEMBER 5, 2023

Under the IRA, drugs selected for the Program remain “selected drugs” until HHS determines that there is at least one product that is both “approved or licensed” as a generic or biosimilar of the selected drug and “marketed pursuant to such approval or licensure.”

Marketing 40

Marketing Marketing Government Litigation 40

Patently-O

JULY 31, 2024

They also argue that this has created an environment where large, multinational companies are incentivized to engage in “predatory infringement,” finding it cheaper to infringe patents than to license them, especially when the patent holders are “undercapitalized entities” such as individual, universities, or start-ups.

Patent 53

Patent Patent Infringement Law Settlement 53

LexBlog IP

JANUARY 25, 2024

FDA Approvals In 2023, there were 23 FDA approvals of Biologic License Applications , including for Vertex’s CASGEVY and Bluebird’s LYFGENIA, the first cell-based gene therapies for the treatment of sickle cell disease. As we kick off 2024, we reflect on regulatory developments in the biologics and biosimilars space in 2023.

Marketing 40

Marketing Marketing Licensing Litigation 40

Fish & Richardson Trademark & Copyright Thoughts

FEBRUARY 4, 2021

For the first time since FDA licensed the first biosimilar, Sandoz’s Zarxio ® (filgrastim-sndz), in 2015, the United States saw a decrease in annual biosimilar approvals in 2020. No earlier than July 31, 2023 per settlement. No earlier than November 20, 2023 per settlement. . No earlier than June 30, 2023 per settlement.

Litigation 52

Litigation Settlement Marketing Marketing 52

TorrentFreak

DECEMBER 3, 2024

The DISH complaint described Jadoo TV’s operation as a “deliberate, multi-year effort” to distribute its exclusively-licensed TV channels without authorization, amounting to direct, contributory, and vicarious infringement under 17 U.S.C. 20, 2025,” the statement reads. Section 501.

Copyright Infringement 56

Copyright Infringement Settlement Copyright Litigation 56

SpicyIP

FEBRUARY 10, 2025

Lodha TM battle Following disagreements over how a family settlement agreement is to be interpreted, the Lodha brothers are tangling over the Lodha trademark. Union Budget 2025-26: Whats in it for Innovation, Tech, Trade and Health? The FM Nirmala Sitharaman on February 1 presented the Union Budget 2025-26. amongst others.

Registering Trademarks 59

Registering Trademarks Trademark Copyright Business 59

Technology & Marketing Law Blog

MARCH 19, 2025

The settlement says: subdivisions (a)(3), (a)(4)(A), and (a)(5) of California Business and Professions Code section 22677 violate the First Amendment of the United States Constitution facially and as applied to Plaintiff The state also must pay X $345,576 to cover its challenge costs. settlement filed Feb. Great job, California.

Social Media 59

Social Media Law Settlement Reporting 59

SpicyIP

DECEMBER 31, 2024

Wishing everyone a prosperous and a healthy new year ahead and hoping that 2025 brings in spicier IP developments to the Indian IP regime, making it a more fair, balanced and effective one! As always, a huge thanks to all our contributors including our readers who engage online as well as offline with our posts and constantly encourage us.

IP 105

IP Invention Patent Copyright 105